<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endometriosis in adolescents: Diagnosis and treatment</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endometriosis in adolescents: Diagnosis and treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endometriosis in adolescents: Diagnosis and treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sawsan As-Sanie, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jessica Shim, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elise DeVore Berlan, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Endometriosis classically refers to the presence of endometrial glands and stroma outside the endometrial cavity and uterine musculature. These ectopic endometrial implants are usually located in the pelvis but can occur nearly anywhere in the body. The disease can occur in adolescents and can be associated with many distressing and debilitating symptoms, or it may be asymptomatic. Despite numerous studies, considerable controversy remains regarding the incidence, pathogenesis, natural history, and optimal treatment of this disorder.</p><p>This topic will discuss endometriosis specifically in adolescents. The disease in adults is reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/134970.html" rel="external">"Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3282.html" rel="external">"Endometriosis: Management of ovarian endometriomas"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7408.html" rel="external">"Endometriosis: Treatment of infertility in females"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3279.html" rel="external">"Female infertility: Reproductive surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6687.html" rel="external">"Clinical features, diagnostic approach, and treatment of adults with thoracic endometriosis"</a>.)</p><p></p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H3720840933"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The prevalence of endometriosis in the general population is not known; estimates vary depending upon the population studied (symptomatic or asymptomatic) and the method of diagnosis (clinical versus surgical). The disease has been reported in 25 to 38 percent of adolescents with chronic pelvic pain [<a href="#rid1">1,2</a>] and 64 percent of those with chronic pelvic pain that undergo laparoscopy [<a href="#rid3">3,4</a>]. The prevalence among adolescents undergoing laparoscopy for pelvic pain not controlled with oral contraceptive pills and nonsteroidal anti-inflammatory drugs is 50 to 70 percent [<a href="#rid5">5-7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of onset</strong> – Two-thirds of adult women with endometriosis report that their symptoms started before age 20 [<a href="#rid8">8</a>]. Although it had been assumed that endometriosis presented only after many years of menstruation, this was incorrect: symptomatic cases have been documented prior to premenarche in girls who have started breast development (endometriosis is stimulated by estrogen) and in others soon after menarche [<a href="#rid9">9-11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetic association</strong> – Some adolescents may have a genetic predisposition to developing endometriosis. In one study of 123 patients with histologically proved endometriosis, first degree female relatives of affected patients were significantly more likely to have been diagnosed with endometriosis than relatives of controls (7 versus 1 percent) [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Many theories have been proposed to explain the etiology of endometriosis. No single theory explains all cases, and all of the theories help to explain some aspects of the disease. The types and frequencies of pathogenetic mechanisms may be different in adolescents and postpubertal/premenarchal endometriosis than in adult endometriosis. It is likely that the cause of endometriosis is multifactorial, with contributions from several of the proposed mechanisms. (See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact", section on 'Pathogenesis'</a>.)</p><p>The following theories for the pathogenesis of endometriosis have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>The implantation or retrograde menstruation theory suggests that endometrial tissue from the uterus is shed during menstruation and transported through the fallopian tubes, thereby gaining access to, and implanting on, pelvic structures [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1">This theory is supported by the observation that endometriosis occurs most commonly in the dependent portion of the pelvis. In addition, obstructive congenital anomalies of the female genital tract that enhance retrograde menstrual flow, such as vaginal agenesis, imperforate hymen, and transverse vaginal septum, have been associated with endometriosis in the adolescent population [<a href="#rid10">10,14,15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometriosis in locations outside the pelvis may be secondary to dissemination of endometrial cells or tissue through lymphatics and blood vessels [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The coelomic metaplasia theory proposes that the coelomic (peritoneal) cavity contains undifferentiated cells or cells capable of dedifferentiating into endometrial tissue [<a href="#rid17">17</a>]. This theory is based upon embryologic studies demonstrating that all pelvic organs, including the endometrium, are derived from cells lining the coelomic cavity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The direct transplantation theory is the probable explanation for endometriosis that develops in episiotomy after vaginal delivery or the abdominal wall after cesarean section.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cellular immunity theory suggests that a deficiency in cellular immunity allows ectopic endometrial tissue to proliferate [<a href="#rid18">18-20</a>]. Alterations in cellular immunity may work in conjunction with retrograde menstruation as a mechanism for endometriosis development.</p><p></p><p>Several early life risk factors may also contribute to the development of endometriosis in adolescence. Prior studies have postulated breastfeeding in early life, secondhand smoke during childhood [<a href="#rid21">21</a>], and sexual and physical abuse in early life [<a href="#rid22">22</a>] are associated with increased risk of endometriosis. Dietary exposures in adolescence may impact the risk of subsequent endometriosis, such as dairy intake [<a href="#rid23">23</a>]. However, early life and adolescent interventions to reduce risk of endometriosis remain understudied and causality cannot be inferred from the above studies.</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Heightened awareness of the clinical manifestations of endometriosis in the adolescent may decrease the length of time between patient presentation and clinical diagnosis, which averages nine years [<a href="#rid8">8</a>]. Ideally, early diagnosis and treatment of endometriosis will prevent or slow disease progression [<a href="#rid24">24</a>], and subsequently decrease the adverse long-term effects of the disease (chronic pain, endometriomas, infertility), and thus improve the quality of life of adolescents and women with this disorder.</p><p>Adolescents with endometriosis usually have both acyclic and cyclic pain/cramps (severe, progressive dysmenorrhea)  (<a class="graphic graphic_table graphicRef72066" href="/z/d/graphic/72066.html" rel="external">table 1</a>) [<a href="#rid25">25</a>]; isolated cyclic pain is the least common pain presentation [<a href="#rid7">7</a>]. Bowel symptoms (eg, rectal pain, constipation, painful defecation that may be cyclic, rectal bleeding) and bladder symptoms (eg, dysuria, urgency, hematuria) are also common [<a href="#rid7">7</a>]. Most adolescents with endometriosis have superficial disease, while deeply infiltrative endometriosis and ovarian endometriomas and infertility are rare in this age group.</p><p>There can be overlap of symptoms that involve pelvic pain and gastrointestinal (GI) symptoms. If the young patient's pain is cyclic in nature and worse with their periods, a gynecologic evaluation may be warranted prior to a GI evaluation. GI symptoms can be common with endometriosis, but GI disorders do not typically have a cyclic relationship to menstrual cycles. Acyclic pelvic pain may be a strong predictor for the likelihood of irritable bowel syndrome (IBS), thus screening for IBS should be considered [<a href="#rid26">26</a>]. If the adolescent has pain and a family history of endometriosis and/or infertility, a gynecologic evaluation may be the best first option for evaluation prior to a GI evaluation.</p><p>By contrast, adults with endometriosis commonly have cyclic pain, and present with dysmenorrhea, dyspareunia, a pelvic mass, infertility, or chronic pelvic pain. (See  <a class="medical medical_review" href="/z/d/html/134970.html" rel="external">"Endometriosis: Clinical features, evaluation, and diagnosis", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Causes of pelvic pain in adolescents include pregnancy (intrauterine or ectopic), appendicitis, pelvic inflammatory disease, müllerian abnormalities with outflow obstruction, hernia, bowel disease, urinary tract disease, and musculoskeletal issues. The etiology and evaluation of chronic pain in this population are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/111.html" rel="external">"Chronic abdominal pain in children and adolescents: Approach to the evaluation", section on 'Etiology'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H8"><span class="h2">History</span><span class="headingEndMark"> — </span>Questions that should be addressed by the history are listed in the figure  (<a class="graphic graphic_table graphicRef76235" href="/z/d/graphic/76235.html" rel="external">table 2</a>). Having the patient keep a diary documenting the frequency and character of their pain will help determine whether the pain is cyclic, and if it is related to bowel or bladder function. Patients with a history of sexual or physical abuse may be at increased risk of developing chronic pelvic pain [<a href="#rid27">27</a>], but this should not preclude further evaluation for endometriosis. Mental health screening should also be considered as there is an increased risk of anxiety and depression in adolescents with symptoms of pelvic pain [<a href="#rid28">28</a>]. The patient's family may be involved in contributing to the history, but the history, including sexual activity, should be taken in private when appropriate. School absenteeism or decreased engagement in prior work, activities, or relationships should be assessed.</p><p>A family history should be obtained, and it should be noted that if a patient has a first-degree relative with endometriosis or suspected disease, such as pelvic pain or infertility. In such situations, the patient is advised of a seven times greater risk of having endometriosis compared with the general population [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1017430311"><span class="h3">Associated diseases</span><span class="headingEndMark"> — </span>It should be noted that there is a higher than expected rate of autoimmune diagnoses in women with endometriosis compared with the general population [<a href="#rid30">30-35</a>]. There is an increased rate of arthritis, inflammatory bowel disease, thyroid disease, migraine headaches, systemic lupus erythematosus, Sjögren's disease, postural orthostatic hypotension, and multiple sclerosis. </p><p class="headingAnchor" id="H9"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The goal of the physical examination is to determine the etiology of the pain and to rule out an ovarian tumor or obstructive anomaly of the reproductive tract. The approach to abdominopelvic examination depends on the patient. Although important, it may not be possible to perform a complete pelvic examination in all adolescents, particularly those who have not been sexually active or are unable to use tampons. A pelvic exam should not be a barrier to further evaluation, diagnosis, and treatment of endometriosis.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5417.html" rel="external">"Congenital anomalies of the hymen and vagina"</a>.)</p><p></p><p>The abdominal examination is usually normal but can be helpful in localizing the pain. Evidence of a reticulated pattern of hyperpigmentation, called erythema ab igne, would suggest chronic exposure to heat for pain relief (eg, heating pad, hot water bottle).</p><p>We do not typically perform speculum and bimanual exams on adolescents. These exams will likely be low yield and uncomfortable and generally do not add information that cannot be obtained from imaging studies. On pelvic examination, adolescents rarely have uterosacral nodularity, a common finding in adults with deep or advanced disease. Adnexal enlargement may be palpable if an endometrioma is present, but these masses are also rare in adolescents [<a href="#rid36">36</a>]. Sonographic examination can be performed to augment (or in place of) a limited physical examination and identify/exclude causes of abdominopelvic pain other than endometriosis. (See <a class="local">'Imaging studies'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Laboratory</span><span class="headingEndMark"> — </span>Laboratory tests to consider include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count and erythrocyte sedimentation rate, which may suggest the presence of an acute or chronic inflammatory process but are not elevated due to endometriosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis and urine culture to identify pain originating in the urinary tract (eg, cystitis, stone)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test and tests for sexually transmitted infections (gonorrhea, chlamydia), when appropriate</p><p></p><p>CA 125 is most commonly used as a biomarker for ovarian cancer, but can be elevated in other conditions, including endometriosis. A serum CA 125 level is not a useful screening test due to its high rate of false positives as it is nonspecific  (<a class="graphic graphic_table graphicRef81621" href="/z/d/graphic/81621.html" rel="external">table 3</a>). It has been used occasionally to follow the progress of disease in patients who have histologically or visually confirmed endometriosis at surgery [<a href="#rid37">37</a>], but we prefer to rely on the patient's report of self-specific symptoms, which is typically pain, to follow endometriosis, and thus do not use CA 125 in clinical management. (See  <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">"Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>In adult women with endometriosis, sonography and magnetic resonance imaging (MRI) can identify ovarian endometrioma and deeply infiltrative endometriosis, which are signs of more advanced disease. However, these tend to be less useful in diagnosis of endometriosis in adolescents since endometriomas and deep endometriosis are rare and the typical superficial peritoneal lesions of adolescent endometriosis cannot be appreciated with imaging. Still, ultrasound and MRI may be useful to identify/exclude several structural causes of pelvic pain in adolescents, such as ovarian torsion or hemorrhage, tumors, genital tract anomalies. </p><p>MRI can be helpful to better define an abnormality suspected by sonography, but should not be used as a first-line imaging test because of its expense and poor sensitivity for detecting superficial peritoneal lesions, which is the most common form of endometriosis in adolescents [<a href="#rid38">38-40</a>]. Computed tomography is also an insensitive test in the diagnostic evaluation of endometriosis, unless an endometrioma is identified. (See  <a class="medical medical_review" href="/z/d/html/3282.html" rel="external">"Endometriosis: Management of ovarian endometriomas"</a>.)</p><p class="headingAnchor" id="H3757374928"><span class="h1">OUR APPROACH</span><span class="headingEndMark"> — </span>The discussion below on the decisions leading to diagnosis and treatment options are not as straightforward as the headings imply  (<a class="graphic graphic_algorithm graphicRef128512" href="/z/d/graphic/128512.html" rel="external">algorithm 1</a>). While there is a clear statement on the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and combined estrogen-progestin contraceptives (or progestin-only therapy for those with a contraindication or who prefer not to use estrogen) for the treatment of dysmenorrhea, the next steps for clinical evaluation and management of persistent pain are less clear. If an adolescent has continued pain on hormonal therapy and NSAID therapy after three months of treatment, there are no data suggesting that a different estrogen-progestin or progestin-only contraceptive will improve their symptoms. Thus, we advise moving to the next step for evaluation rather than opting for an alternative medical treatment. </p><p>Patients whose pain persists after an initial trial of hormonal contraception with NSAID have several options for continued evaluation and management  (<a class="graphic graphic_algorithm graphicRef128512" href="/z/d/graphic/128512.html" rel="external">algorithm 1</a>). Traditional gynecologic teaching has promoted laparoscopy for surgical diagnosis and surgical management of endometriosis. However, in adult patients with symptoms suggestive of endometriosis, clinical diagnosis followed by medical management and/or surgical management are both viewed as reasonable options. Given the safety of hormonal suppression and similar efficacy to laparoscopy, the thinking has evolved that patients can be given a clinical diagnosis of endometriosis without the need for surgery. For patients who wish to avoid surgery, treatment includes medical suppression with continuous combination estrogen-progestin therapy, progestin alone, GnRH agonist with add-back, or GnRH antagonist. Selection of a specific agent is driven by ease of use, side effects, cost, and availability. In this setting, surgery is reserved for individuals whose pain does not resolve on medical therapy or those who desire a definitive surgical diagnosis before initiating treatment. </p><p>As supporting data are limited, the decision to pursue surgical diagnosis versus attempt continued medical treatment based on a clinical diagnosis is guided by patient and family preferences. As part of the shared decision-making process, issues for discussion and consideration include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unknown impact of medical therapy alone on disease progression</strong> – It is not known if medical therapy alone suppresses the progression of endometriosis and adhesions. This is an important issue as progression of either can lead to worsened symptoms over a lifetime and impaired fertility. For adolescent patients, there is a small body of data demonstrating that disease progression is suppressed in those who have surgical management followed by medical suppression [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical versus medical risk</strong> – Not all adolescent individuals are low risk for surgery or candidates for preferred medical therapy. Complicating factors include prior abdominal surgery, presence of congenital gynecologic anomalies, and underlying medical conditions. Both the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789241549158&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1%2BeMBqFM7dNdQ9NPFnY3uWg%3D%3D&amp;TOPIC_ID=7415" target="_blank">World Health Organization Medical Eligibility Criteria for Contraceptive Use</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fmmwr%2Fmec%2Fsummary.html&amp;token=gn9CxBU9SK4%2Bjug8DleFYAmCahKbgv18S9Zgv5fBNxTGoMdTGRC8XnfLV%2BmDF%2FKgq%2FUbcwPNhHygS%2BUPWWe15o2kSqIPMCtrmL2KJwaUlwQ%3D&amp;TOPIC_ID=7415" target="_blank">US Medical Eligibility Criteria for Contraceptive Use</a> maintain evidence-based recommendations for use of contraceptive methods in the context of a range of medical conditions and personal characteristics [<a href="#rid41">41,42</a>]. The benefits and side effects of estrogen-containing contraceptives are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7399.html" rel="external">"Combined estrogen-progestin contraception: Side effects and health concerns"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Desire for definitive diagnosis before initiating treatment</strong> – Some individuals and/or their families may prefer to avoid hormonal treatment unless there is a demonstrated need. In addition, patients with endometriosis are typically treated with medical suppression until they desire pregnancy, which can be decades later. Not all individuals are comfortable committing to years of therapy based on a clinical diagnosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormonal treatment if continued pain</strong> – If endometriosis is not identified at time of laparoscopy, hormonal treatment is often still recommended for patients with dysmenorrhea or cyclic exacerbation of pelvic pain.</p><p></p><p>Regardless of which path is selected, for individuals with continued pain despite treatment with cyclic hormones and NSAIDs, the diagnosis is most likely endometriosis, and the treatment plan that most improves quality of life and functionality should be selected.</p><p class="headingAnchor" id="H12"><span class="h1">TRIAL OF MEDICAL THERAPY FOR DYSMENORRHEA</span></p><p class="headingAnchor" id="H13"><span class="h2">NSAIDs and hormonal therapy</span><span class="headingEndMark"> — </span>Medical treatment of dysmenorrhea is appropriate prior to considering surgical intervention for diagnosis/treatment of endometriosis in adolescents with dysmenorrhea and/or who have difficulty participating in normal activities, are missing school, or avoiding extracurricular activities because of pelvic pain. A three month trial of nonsteroidal anti-inflammatory agents (NSAIDs) is a reasonable approach when the pain evaluation suggests a nonacute gynecologic source, such as primary dysmenorrhea or endometriosis  (<a class="graphic graphic_table graphicRef71912" href="/z/d/graphic/71912.html" rel="external">table 4</a>) [<a href="#rid43">43</a>]. The medication should be started before the expected onset of severe pain, if possible. (See  <a class="medical medical_review" href="/z/d/html/5847.html" rel="external">"Primary dysmenorrhea in adolescents"</a>.)</p><p>Hormonal therapy, such as a cyclic low-dose combination estrogen-progestin oral contraceptive pill (OC), or progestin-only therapy (oral, injectable, or implantable), should be given with the NSAIDs [<a href="#rid43">43</a>]. There are no data suggesting one contraceptive pill formulation is better than another for the treatment of dysmenorrhea. Use of hormonal therapy leads to decidualization and subsequent atrophy of ectopic and eutopic endometrial tissue, thereby decreasing bleeding and, in turn, reducing bleeding-related pain. These agents are particularly useful in adolescents also needing contraception or menstrual management, which NSAIDs would not provide. The vaginal ring and transdermal contraceptive patch are other examples of methods of combined hormonal contraception and are acceptable alternatives to OCs. The vaginal ring may not be a desirable choice for some adolescents, such as those who do not utilize tampons. All of these methods are safe and effective if given cyclically, and the oral pill and vaginal ring may be used in an extended or continuous fashion [<a href="#rid44">44-46</a>]. The extended cycle regimen has been successful in women whose pain did not respond to cyclic therapy but is associated with more unscheduled bleeding. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Estrogen-progestin contraceptives'</a> and  <a class="medical medical_review" href="/z/d/html/5423.html" rel="external">"Hormonal contraception for menstrual suppression"</a> and  <a class="medical medical_review" href="/z/d/html/107.html" rel="external">"Contraception: Issues specific to adolescents", section on 'Pill, patch, or ring'</a>.)</p><p>If the pain does not resolve with NSAIDs and hormonal therapy, then further evaluation is necessary. </p><p class="headingAnchor" id="H14"><span class="h2">Gonadotropin-releasing hormone agonists</span><span class="headingEndMark"> — </span>For adult women in whom endometriosis is the suspected cause of the pain, an expert panel opined that a trial of medical therapy with a gonadotropin-releasing hormone (GnRH) agonist is justified provided that there are no other indications for surgery (eg, suspicious adnexal mass, urinary or gastrointestinal tract obstruction) [<a href="#rid47">47</a>]. The empiric utilization of a GnRH agonist allows patients with chronic pelvic pain and a high probability of endometriosis to avoid a diagnostic surgical procedure before beginning this therapy. Doses are described below. (See <a class="local">'GnRH agonists'</a> below.)</p><p>Placebo controlled randomized trials have confirmed the efficacy of this approach [<a href="#rid48">48</a>]. The only randomized trial that directly compared use of a GnRH agonist (<a class="drug drug_general" data-topicid="8500" href="/z/d/drug information/8500.html" rel="external">goserelin</a>) with low-dose cyclic OCs in adult women with pelvic pain associated with endometriosis showed that both drugs provided significant relief of pain, but goserelin was superior for treatment of dyspareunia [<a href="#rid49">49</a>].</p><p>We do not utilize empiric GnRH agonists for adolescents 18 years of age or younger because we have concerns about potential adverse long-term effects on bone formation and bone mineral density [<a href="#rid50">50</a>]. Additionally, some guardians are not comfortable with a trial of empiric therapy due to worries about using a medication with adverse side effects without a definitive diagnosis. The American College of Obstetricians and Gynecologists does not endorse the use of empiric GnRH agonist therapy for treatment of presumed endometriosis in young women under age 18, but considers it an option for consenting women age 18 or over [<a href="#rid43">43</a>]. Most bone mass in females has accumulated by age 18 [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H15"><span class="h1">PATIENTS WHO FAIL THERAPY FOR DYSMENORRHEA</span><span class="headingEndMark"> — </span>A definitive diagnosis of endometriosis should be established for adolescents who have persistent pain after three to six months of hormonal therapy and nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of dysmenorrhea [<a href="#rid43">43</a>]. Laparoscopy is the gold standard for diagnosis of endometriosis, although there has been a movement to increase the use of clinical diagnosis and treat endometriosis-associated pain without the need for a surgical diagnosis [<a href="#rid52">52,53</a>]. </p><p>When pain persists despite dysmenorrhea therapy, we talk with the adolescent and family to determine the amount of pain that is being experienced. We suggest that if the pain interferes with activities of daily life or places them at a disadvantage in academics, sports, or social activities compared with others, then we, and the American College of Obstetricians and Gynecologists, have classically recommended that the patient undergo laparoscopy for definitive diagnosis [<a href="#rid43">43</a>]. Typically, laparoscopy is performed after three to six months of pain [<a href="#rid43">43</a>], but waiting this long may result in pain continuing to interfere with school and social activities. Therefore, it may be necessary to proceed with laparoscopic evaluation sooner. At surgery, up to 70 percent of adolescents with chronic pelvic pain that has not responded to a trial of NSAIDs and cyclic oral contraceptive pills are found to have endometriosis [<a href="#rid7">7</a>]. These data are from studies in the early 1990s. Based on advances in laparoscopic imaging with high definition digital technology, the current rate is likely higher.</p><p class="headingAnchor" id="H16"><span class="h2">Diagnostic (and therapeutic) laparoscopy</span><span class="headingEndMark"> — </span>The gynecologic surgeon should have experience operating on patients in this age range or consult with an appropriate pediatric gynecologist or pediatric surgeon. In addition to diagnosis, surgical management of the endometriosis should be part of the primary surgery. Purely diagnostic laparoscopy followed by referral for definitive surgery should be avoided whenever possible. </p><p>Endometriotic implants can have a variable appearance in this age group and differ from findings commonly seen in adults  (<a class="graphic graphic_picture graphicRef65789" href="/z/d/graphic/65789.html" rel="external">picture 1</a>) [<a href="#rid54">54</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common findings</strong> – The only series that objectively compared endometriosis lesions in adolescents with those in adults found red flame lesions were more common and powder burn lesions less common in adolescents than in adult patients [<a href="#rid55">55</a>]. This is consistent with the theory that powder burn lesions represent older, more advanced implants. Clear and red lesions may be the more painful lesions of endometriosis  (<a class="graphic graphic_table graphicRef65934" href="/z/d/graphic/65934.html" rel="external">table 5</a>) [<a href="#rid56">56</a>]. Peritoneal windows or defects are also common in adolescents and should be recognized as suggestive of endometriosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identification of clear lesions</strong> – Care must be taken to identify subtle endometriotic lesions that often appear as clear, shiny peritoneal vesicles. Some surgeons have reported that visualization through a liquid medium, such as <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, may facilitate identification [<a href="#rid57">57</a>]. After all the lesions have been located, the fluid is removed so that the lesions can be ablated or excised.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of biopsy if no lesions</strong> – If no evidence of endometriosis is identified, a posterior cul-de-sac biopsy to exclude the presence of microscopic disease should be performed and may identify lesions not visualized on laparoscopy. One study of nondirected biopsies found a low prevalence of microscopic endometriosis [<a href="#rid58">58</a>], while another reported a significant rate in adults [<a href="#rid59">59</a>]. Our experience at Boston Children's Hospital is that we find microscopic endometriosis in 3 percent of adolescent girls with chronic pelvic pain unresponsive to conventional therapy and with a visually normal pelvis [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometriosis documentation</strong> – Endometriosis operative findings should be documented in a standardized fashion using a surgical staging system. There are several staging systems reported, and the most commonly used is the revised ASRM Classification of Endometriosis  (<a class="graphic graphic_figure graphicRef66366" href="/z/d/graphic/66366.html" rel="external">figure 1</a>). Standardized staging will facilitate follow-up and comparison if future surgery is performed [<a href="#rid54">54</a>]. Although most adolescents present with Stage I to II disease, in one series, 11 of 36 adolescents with endometriosis had stage IV disease [<a href="#rid55">55</a>]. In general, the stage of disease does not correlate with degree of pain. When counseling patients postoperatively, it is important to remember that the severity of symptoms does not correlate with the extent or location of lesions  (<a class="graphic graphic_table graphicRef75516" href="/z/d/graphic/75516.html" rel="external">table 6</a>) [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Surgical treatment</span><span class="headingEndMark"> — </span>Most adult women experience a reduction in pain after surgical treatment [<a href="#rid61">61,62</a>]. There are no large studies in adolescents. One retrospective cohort study of 85 adolescents (mean age 16.3±2.4 years) reported that pain had disappeared in 42 percent and improved in 38 percent at mean follow-up of 56 months after surgery [<a href="#rid63">63</a>]. Twenty percent reported no change or worsened pain.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical treatment of lesions</strong> – Excision or destruction of superficial peritoneal endometriosis should be performed at the time of laparoscopy [<a href="#rid53">53,64,65</a>]. In adults with stage I or II disease, there is no difference in outcome with excision versus ablation of endometriosis, but surgical excision should be performed for deeply infiltrative lesions [<a href="#rid66">66-71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrioma </strong>– While ovarian endometriomas are an uncommon presentation in adolescents, first-line treatment in adolescents should be cystectomy versus oophorectomy. Conservative surgical treatments should be considered as opposed to definitive (ie, hysterectomy with or without oophorectomy) to preserve fertility and hormonal production.</p><p></p><p>Radical excisional surgery or peritoneal stripping has not been shown to be more effective than ablation or excision in adolescents and may be associated with increased risk of adhesion formation [<a href="#rid43">43,72</a>]. Lysis of adhesions is also performed at the time of surgery. Laparotomy is rarely required. Any large endometriotic cysts should be removed, with preservation of as much ovarian tissue as possible. Care must be taken to avoid damage to the ureters, major blood vessels, bowel, and bladder. (See  <a class="medical medical_review" href="/z/d/html/16673.html" rel="external">"Endometriosis: Surgical management of pelvic pain"</a>.)</p><p>It should be noted that no surgical procedure or medical therapy results in a cure for endometriosis. Surgery alone is not adequate treatment for endometriosis as there can be microscopic residual disease that must be suppressed with medical therapy [<a href="#rid47">47</a>]. Symptoms will return within one year in approximately 50 percent of adult women who receive only surgical therapy [<a href="#rid47">47,61,66,73</a>]. Thus, medical treatment is typically initiated postoperatively. (See <a class="local">'Postoperative medical treatment'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h1">POSTOPERATIVE MEDICAL TREATMENT</span><span class="headingEndMark"> — </span>There are no long-term follow-up data describing the natural history of untreated endometriosis first detected in adolescents; we do not know the proportion of endometriosis that will progress to more advanced disease if left untreated. </p><p>The general consensus is that adolescents with histologically confirmed endometriosis should receive hormonal medical treatment after surgical ablation/resection until they are ready to attempt pregnancy [<a href="#rid43">43</a>]. Compared with eutopic endometrium, endometriotic implants are characterized by overproduction of prostaglandins and local production of estrogens and cytokines, which synergize the activities of each other, promote implantation of ectopic endometrium, and cause the pain associated with endometriosis. The rationale for medical therapy is inhibition of prostaglandin synthesis, decidualization and subsequent atrophy of residual ectopic endometrial tissue, and reduction of ovarian estrogen production, thereby inhibiting the growth and activity of the ectopic endometrium.</p><p>The goal of medical therapy is to manage pain due to residual disease, allow the patient to function comfortably in their daily activities, and suppress disease recurrence or progression, which could impair fertility. Long-term follow-up data in adolescents show that endometriosis that is surgically identified and destroyed and then followed by medical therapy tends not to progress [<a href="#rid24">24,74</a>]. The follow-up study reported that while disease can persist following surgical resection, it does not tend to progress with surgical management followed by medical suppression. This study also reported no increase in the rates of adhesion formation from the initial surgical procedure [<a href="#rid24">24</a>]. There are limited data on the course of adolescents who undergo complete excision of visible endometriosis but do not undertake postoperative hormonal suppression [<a href="#rid75">75</a>]. It is notable that radical excisional surgery for Stage I or II superficial disease also has the risk of subsequent adhesion formation [<a href="#rid76">76</a>]. </p><p>Treatment efficacy should be assessed regularly, and we do this by asking the patient to rate their pain on a scale of 0 to 10 at each visit. We educate patients that they may not become pain free, but the medications can be adjusted to maximize pain relief and promote participation in school and social activities. Support groups for adolescents with endometriosis are available and can be useful (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=9SOQ31M5muHbxxUii9uduj7uOdQP%2BNVKJGoE4M4lyiOJKXEoosD%2FJno5DMXZnUfG&amp;TOPIC_ID=7415" target="_blank">www.youngwomenshealth.org</a>).</p><p>Several medical therapies are available, each with differing risks, benefits, and side effect profiles [<a href="#rid72">72,77</a>]. The choice of treatment depends upon the severity of the patient's symptoms, the extent of disease, compliance, and need for contraception. Although numerous options have been described for the treatment of endometriosis [<a href="#rid5">5,50</a>], combination hormonal therapy or gonadotropin-releasing hormone (GnRH) agonists are usually used for first-line therapy. For adolescents with confirmed endometriosis, we offer both therapies to those ages 16 or over, but use only continuous combination hormonal and progestin-only therapies in those under 16 years of age out of concern about the effects of GnRH agonists on the formation of normal bones and bone density [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H19"><span class="h2">Continuous hormonal therapy</span><span class="headingEndMark"> — </span>Use of continuous hormonal therapy after surgery may retard progression of disease and control any remaining pain [<a href="#rid45">45</a>]. (See <a class="local">'NSAIDs and hormonal therapy'</a> above.)</p><p class="headingAnchor" id="H6499963"><span class="h3">Combination estrogen-progestins</span><span class="headingEndMark"> — </span>Combination therapy can be used to suppress menstruation and induce a "pseudo-pregnancy" state for suppression of endometriosis and endometriosis associated pain. A monophasic progestin dominant pill is most effective for the suppression of menses. It is important for adolescents to be reminded that, for this treatment to be successful, the pill must be taken at the same time daily. For many adolescents, the time they take their medication may be in the evening, as most adolescents do not get up at the same time on weekdays and weekends. If the pill is delayed or missed, there appears to be an increased risk of breakthrough bleeding.</p><p class="headingAnchor" id="H20"><span class="h2">Progestins</span><span class="headingEndMark"> — </span>Progestins inhibit endometriotic tissue growth by causing initial decidualization and eventual atrophy. They also inhibit pituitary gonadotropin secretion and ovarian hormone production, resulting in a mildly hypoestrogenic state relative to normal.</p><p>The most commonly used progestational agents are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a> (0.35 mg daily by mouth)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a> acetate (5 to 15 mg daily by mouth)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">Medroxyprogesterone acetate</a> (30 to 50 mg daily by mouth)</p><p class="bulletIndent1"><span class="glyph">●</span>Depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (150 mg intramuscularly every one to three months)</p><p></p><p>Families should be reassured that contraception may be used for noncontraceptive benefits (eg, for endometriosis) and contraception does not increase the likelihood of riskier sexual behavior [<a href="#rid79">79</a>]. However, some families of younger patients may be more interested in use of oral <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>, as they are not approved as contraceptive agents. </p><p>It should be noted that although a progestin only, <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate has been shown to be converted to a low amount of ethinyl estradiol [<a href="#rid80">80</a>].</p><p>Each of these therapies improves symptoms in approximately 80 to 100 percent of patients with endometriosis [<a href="#rid81">81-85</a>]. <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a> acetate alone has been shown to be effective and well tolerated in adolescents [<a href="#rid85">85</a>]. With higher doses of norethindrone acetate (15 mg per day), liver adenomas have been reported as with combination estrogen-progestin pills, and thus, we typically use doses less than 10 mg per day [<a href="#rid86">86</a>]. The etonogestrel subdermal implant has also been used successfully, but experience is limited [<a href="#rid87">87-90</a>]. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Progestins'</a>.)</p><p>Potential bothersome side effects of progestins include weight gain, bloating, depression, and unscheduled bleeding [<a href="#rid8">8</a>]; however, many patients tolerate this therapy very well [<a href="#rid84">84</a>]. Oral progestin therapy should be considered prior to long-term intramuscular injections so that side effects can be identified and addressed or the medication easily discontinued.</p><p><a class="drug drug_general" data-topicid="121397" href="/z/d/drug information/121397.html" rel="external">Drospirenone</a> (commercial name Slynd) is a progestin-only contraceptive pill that may also be considered, although its use for endometriosis has not been studied. </p><p>The long-term utilization of depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> has been shown to result in loss of bone density, which is reversible after discontinuation of the progestin. </p><p>Progestin intrauterine devices (IUDs) deliver the progestin <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a> (LNG) to the local uterine environment. Many use <a class="drug drug_general" data-topicid="104541" href="/z/d/drug information/104541.html" rel="external">LNG IUDs</a> for the treatment of dysmenorrhea and endometriosis-associated pain. No LNG IUD is approved by the US Food and Drug Administration for treatment of endometriosis-associated pain. We commonly offer LNG IUD placement at the time of anesthesia for endometriosis, such as the time of laparoscopy, to potentially minimize the discomfort of pelvic examination for the adolescent. We consider the simultaneous use of systemic hormonal therapy with the IUD as patients may continue to experience bleeding and pain with the IUD is used alone for endometriosis management [<a href="#rid91">91</a>]. This is expected to inhibit ovulation more consistently, and thus reduce the risk of hemorrhagic ovarian cysts and ovarian endometriomas. The types of LNG IUDs, patient selection, insertion, and management of complications are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/116579.html" rel="external">"Intrauterine contraception: Background and device types", section on 'Levonorgestrel IUD'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3267.html" rel="external">"Intrauterine contraception: Insertion and removal"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications"</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h2">GnRH agonists</span><span class="headingEndMark"> — </span>GnRH agonists can be prescribed for adolescents with laparoscopically confirmed endometriosis who are at least 16 years old. While GnRH agonists are used in adolescents younger than 16 with precocious puberty, treatment duration is shorter for precocious puberty, and therefore, the outcomes and risks cannot be extrapolated to young postpubertal women with endometriosis. For GnRH therapy, our preference is depot <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate (11.25 mg intramuscularly every three months); it is <strong>always</strong> given with add-back therapy. We use the three month formulation to improve compliance with therapy. Occasionally, some patients who receive a one-month formulation experience the expected "flare effect" (increased pain and bleeding) and then do not return for their second one month injection. With the three month formulation, patients who have increased pain and bleeding with the flare effect will have the GnRH agonist in their system for three months and thus continue to benefit from the subsequent suppression. <a class="drug drug_general" data-topicid="9673" href="/z/d/drug information/9673.html" rel="external">Nafarelin</a> nasal spray (one puff twice daily intranasally) is an alternative GnRH agonist, especially in younger adolescents, since the suppression appears to be less than with the intramuscular formulation. Due to the typical twice daily dosing, compliance is often unpredictable in the adolescent population. The dose can thus be titrated to less than twice daily dosing as long as estradiol levels and menses are suppressed. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists"</a>.)</p><p>Over 90 percent of patients will become amenorrheic and hypoestrogenic on this dose of <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> [<a href="#rid92">92</a>]. Side effects of GnRH analogs without add-back therapy include hot flashes, headaches, difficulty sleeping, mood swings, depression, and vaginal dryness; therefore, we do not utilize GnRH agonist therapy without add-back therapy. Menses typically return 60 to 90 days after cessation of intramuscular leuprolide therapy.</p><p>Generally, initial treatment with a GnRH agonist is continued for six months [<a href="#rid93">93</a>]. Upon completion of this initial six month course of GnRH agonist therapy, the patient must then choose a treatment course. One common option is a return to a continuous combined hormonal contraceptive, as described above. GnRH-agonist therapy with add-back has not been approved for use beyond 12 months by the U.S. Food and Drug Administration (FDA) [<a href="#rid93">93</a>], but if the patient is not able to tolerate continuous combination hormonal or <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> only therapy, then long-term utilization of a GnRH agonist with add-back can be prescribed. A baseline bone density assessment is obtained after the initial six to nine months of therapy and is then repeated every two years. If bone density remains stable, then the assessment is repeated every two years while the patient is receiving GnRH agonists. (See <a class="local">'Add-back therapy'</a> below.)</p><p class="headingAnchor" id="H22"><span class="h3">Add-back therapy</span><span class="headingEndMark"> — </span>The utilization of add-back therapy can help alleviate the side effects of GnRH agonists without reducing their efficacy, as long as the add-back regimen does not involve high doses of estrogen [<a href="#rid94">94</a>]. Add-back therapy is based upon the "estrogen threshold hypothesis," which is demonstrated in the figure  (<a class="graphic graphic_figure graphicRef53148" href="/z/d/graphic/53148.html" rel="external">figure 2</a>) [<a href="#rid95">95</a>]. Basically, adequate sex steroid (estrogen plus progestin, or progestin alone) is provided to prevent significant bone demineralization, but not enough to stimulate growth of endometriotic tissue.</p><p>Options for sex steroid add-back therapy used in adult women include [<a href="#rid96">96,97</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">Norethindrone</a> acetate (5 mg daily) alone, or</p><p class="bulletIndent1"><span class="glyph">●</span>Conjugated estrogen (0.625 mg) plus either <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate (2.5 or 5 mg) or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (5 mg daily)</p><p></p><p>Patient satisfaction is higher in adult women with use of <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> compared with the other options  (<a class="graphic graphic_table graphicRef58788" href="/z/d/graphic/58788.html" rel="external">table 7</a>) [<a href="#rid96">96</a>]. Patient satisfaction and bone density were higher in adolescent women with the use of norethindrone acetate plus <a class="drug drug_general" data-topicid="9424" href="/z/d/drug information/9424.html" rel="external">conjugated equine estrogens</a> as compared with norethindrone plus placebos [<a href="#rid77">77,98,99</a>].</p><p class="headingAnchor" id="H23"><span class="h3">Safety</span><span class="headingEndMark"> — </span>The safety of long-term use of a GnRH agonist with add-back therapy in adolescents is under investigation [<a href="#rid78">78</a>]. One study performed serial bone mineral density examinations in 36 adolescents receiving a GnRH agonist with <a class="drug drug_general" data-topicid="10173" href="/z/d/drug information/10173.html" rel="external">norethindrone</a> acetate add-back [<a href="#rid100">100</a>]. Bone density was preserved with this treatment over an 11 month mean treatment period, but preservation of bone density was better at the hip than at the spine. At the hip, 6 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 2 had a Z-score ≤-2.0 SD. At the spine, 11 subjects had a BMD Z-score between -1.0 and -2.0 SD, while 3 had a Z-score ≤-2.0 SD.</p><p class="headingAnchor" id="H2785142251"><span class="h2">GnRH antagonists</span><span class="headingEndMark"> — </span>To date, there are no studies of the use of GnRH antagonists in adolescents. Use of GnRH antagonists in adult patients is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Antagonists'</a>.) </p><p class="headingAnchor" id="H24"><span class="h2">Danazol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a> is a 17-alpha-ethinyltestosterone derivative that creates an acyclic environment. Its mechanisms of action include inhibition of pituitary gonadotropin secretion, direct inhibition of endometriotic implant growth, and direct inhibition of ovarian enzymes responsible for estrogen production. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Danazol'</a>.)</p><p><a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">Danazol</a>'s efficacy in treating mild to moderate endometriosis is equivalent to that of a variety of GnRH agonists [<a href="#rid101">101-107</a>]. Over 80 percent of patients experience relief or improvement of pain symptoms within two months of treatment [<a href="#rid108">108</a>]. Large endometriotic cysts and adhesions do not respond well; surgery is the preferred therapy for these lesions.</p><p>Those taking <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> have side effects that are dose-dependent. Side effects include weight gain, muscle cramps, decreased breast size, acne, hirsutism, oily skin, decreased high density lipoprotein levels, irreversible deepening of the voice, increased liver enzymes, hot flashes, mood changes, and depression [<a href="#rid109">109</a>]. Androgenic side effects are related to decreased sex hormone-binding globulin levels, resulting in an increase of free testosterone.</p><p>Bothersome to intolerable side effects are a common reason for discontinuation of the drug [<a href="#rid109">109</a>]. Although GnRH agonists are also associated with side effects, patients using these drugs report a better quality of life than those taking <a class="drug drug_general" data-topicid="9321" href="/z/d/drug information/9321.html" rel="external">danazol</a> [<a href="#rid110">110</a>]. Given the side effect profile, danazol may be a desirable and well-tolerated option by gender-diverse individuals, including transgender men. Endometriosis has been laparoscopically diagnosed in transmasculine adolescents with pelvic pain while receiving testosterone therapy for gender affirmation [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Nonsteroidal anti-inflammatory agents</span><span class="headingEndMark"> — </span>Nonsteroidal anti-inflammatory agents (NSAIDs) are helpful adjuvant agents for the treatment of pelvic pain associated with endometriosis. In animal models of surgically induced abdominal/peritoneal endometriosis, NSAIDs differentially inhibited lesion establishment and growth, resulting in significantly reduced disease burden [<a href="#rid112">112,113</a>]. This effect may also occur in humans [<a href="#rid114">114,115</a>]. Nonsteroidal therapies, such as antiinflammatory and antiangiogenic drugs, are an emerging area of investigation in treatment of endometriosis [<a href="#rid116">116</a>]. (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain", section on 'Nonsteroidal anti-inflammatory drugs'</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">MANAGEMENT OF RECURRENT PAIN</span><span class="headingEndMark"> — </span>Endometriosis is a chronic and inflammatory disease, which can be progressive, thus pain can recur despite therapy. Management options for recurrent pain include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Change treatment modality</strong> – If adolescents less than 16 years of age have persistent pain associated with endometriosis while taking continuous combination hormonal therapy, then utilization of gonadotropin-releasing hormone (GnRH) agonists with add-back therapy may be needed. One course of six to nine months of therapy may be adequate, followed by return to combination continuous hormonal therapy. Alternatively, for those who do not do well off of GnRH agonist long-term, a GnRH agonist with add-back can be reutilized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolong utilization of a GnRH agonist with add-back therapy</strong> – We have treated patients with surgically diagnosed disease refractory to other medications with prolonged GnRH agonist treatment plus add-back for over 14 years. A baseline bone density evaluation should be obtained prior to starting retreatment with a GnRH agonist or if therapy is to be continued for over six to nine months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitor bone mineral density</strong> – We obtain a baseline bone mineral density assessment after the initial six months of therapy and then repeat it two years later. If bone density is stable on GnRH agonist with add-back therapy, then the test is repeated every two years as long as the patient continues on this regimen. If bone density is decreasing despite add-back therapy, then either surgical ablation/excision or continuous combination hormonal therapy are options. As noted above, the long-term utilization of a GnRH agonist with add-back therapy has not been studied in the adolescent population [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of repeat laparoscopic surgery</strong> – Pain that does not respond to aggressive medical therapy may be due to recurrent endometriosis, endometriomas, and/or pelvic adhesions from endometriosis or prior surgery. However, coexisting pain conditions are common in adolescents with endometriosis and should be thoroughly investigated and treated when present [<a href="#rid117">117</a>]. A repeat laparoscopic procedure should be considered in select patients whose persistent pain and all other potential sources of pelvic pain have been maximally treated. If surgery is to be undertaken, then lysis of adhesions should be performed laparoscopically. All visible lesions of endometriosis should be cauterized, laser ablated, or resected. We utilize adhesion preventive agents laparoscopically following surgical lysis of adhesions. (See  <a class="medical medical_review" href="/z/d/html/2891.html" rel="external">"Postoperative peritoneal adhesions in adults and their prevention"</a>.)</p><p></p><p>A long-term follow-up study reported that adolescents with early stage superficial peritoneal disease do not tend to have disease progression after surgical management followed by medical suppression [<a href="#rid24">24</a>]. That study also reported no increase in adhesion development with that technique. Radical excisional surgery for early-stage superficial peritoneal disease has been questioned to result in adhesions without proven benefit over destruction and excisional surgery [<a href="#rid76">76</a>].</p><p>A multi-disciplinary approach to pelvic pain, with the assistance of pain treatment services and complementary and alternative therapies, should be considered in all adolescents with endometriosis. (See  <a class="medical medical_review" href="/z/d/html/5435.html" rel="external">"Chronic pelvic pain in adult females: Treatment", section on 'Nonpharmacologic therapies'</a>.)</p><p>Social work or similar counselor involvement may be helpful and patients with significant school absenteeism may benefit from academic accommodations. Complementary therapies that may be helpful include acupuncture [<a href="#rid118">118</a>] and pelvic floor physical therapy [<a href="#rid119">119</a>]. Physical therapy may need to be tailored to the adolescent as teens uncomfortable with vaginal insertion may need therapy techniques performed on pelvic floor musculature externally.</p><p class="headingAnchor" id="H574936904"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109439.html" rel="external">"Society guideline links: Endometriosis"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2174.html" rel="external">"Patient education: Endometriosis (Beyond the Basics)"</a>)</p><p></p><p>In addition, there is adolescent endometriosis-specific downloadable information as handouts from the Center for Young Women's Health at Boston Children's Hospital and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F&amp;token=9SOQ31M5muHbxxUii9uduj7uOdQP%2BNVKJGoE4M4lyiOJKXEoosD%2FJno5DMXZnUfG&amp;TOPIC_ID=7415" target="_blank">www.youngwomenshealth.org</a> listed below:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F2014%2F08%2F01%2Fendometriosis-general-information%2F&amp;token=BXssE%2BiYesDIrQ5433GZ2WzJ4%2BIiTfG0QujPaarGFgLs0QmyMxYxNdELlBRMvaE4ajkdnpTe7BKwpbvbJ17Tq3DrJWiXi%2BsD82tXtLD6ep8%3D&amp;TOPIC_ID=7415" target="_blank">Endometriosis</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F2014%2F08%2F01%2Fendometriosis-continuous-hormonal-pills-ocps%2F&amp;token=hjE0LCT%2FZ67gAmr5Kj%2B3id3sNltpOKayC1DJmQOV%2F%2Fl%2FjdGy18fT%2FC9fbXrZmj0P8JnBEf4Mc9ubEA%2B6C59PJeBdUSrPTiB6rF3P9RAUy73GTwOextFamNfELH382WAY&amp;TOPIC_ID=7415" target="_blank">Continuous Hormonal Treatment for Endometriosis</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2F2014%2F08%2F01%2Fendometriosis-hormonal-treatment-overview%2F&amp;token=96IQxugJSec9RkYjPbnn8P0jx25PoMvkWX9dEGqxC1rtM%2F5NCxm1%2FQ0dLZqqA08zMsMzHCGOThLZtG%2F906MOjrWPWeyYqAxVDPnxNFwF9rmvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=7415" target="_blank">Hormonal Treatment Options for Adolescent Endometriosis</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2Fonline-health-chats%2F&amp;token=9SOQ31M5muHbxxUii9uduj7uOdQP%2BNVKJGoE4M4lyiPc7t7cxGIq%2FNm1iigVONqJOk5vh07sDWhRGomoymRMmA%3D%3D&amp;TOPIC_ID=7415" target="_blank">Monthly Live Monitored Chat Rooms for Adolescent with Endometriosis</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fyoungwomenshealth.org%2Fparents%2Fendometriosis-general-information%2F&amp;token=AnAJ6zuBc1Ejm5Ss51iqI8McJ1qraXgMh9Ky%2FhYRLytmVleOa00M9cVxrLgKj5%2B%2B%2FeoGv2S%2BR1raBG8zSLnxUBqfHMaei2GUy8lKxCaMtGE%3D&amp;TOPIC_ID=7415" target="_blank">Parents' Guide to Adolescent Endometriosis</a></p><p></p><p class="headingAnchor" id="H3474473085"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/141288.html" rel="external">"Patient perspective: von Willebrand disease"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment goals</strong> – The goals of therapy are to relieve pain, prevent disease progression, and preserve fertility. An approach for the evaluation and management of adolescents with chronic pelvic pain is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef128512" href="/z/d/graphic/128512.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of symptom onset</strong> – Symptomatic endometriosis commonly occurs in adolescents, in rare cases before menarche. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Common symptoms</strong> – Adolescents with endometriosis usually have both acyclic and cyclic pain. Bowel symptoms (eg, rectal pain, constipation, painful defecation that may be cyclic, rectal bleeding) and bladder symptoms (eg, dysuria, urgency, hematuria) are also common, but uterosacral nodularity and ovarian endometriomas are rare. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – For evaluation of pelvic pain in adolescents, we suggest history and physical examination, pain diary, laboratory evaluation (eg, pregnancy test, complete blood count, erythrocyte sedimentation rate, urinalysis, urine culture, testing for gonorrhea and chlamydia), and ultrasonography to exclude other anatomic causes. However, a bimanual pelvic examination should not be considered a requirement for evaluation of adolescent pelvic pain. (See <a class="local">'Initial evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trial of medical therapy</strong> – Medical treatment of dysmenorrhea is appropriate prior to considering surgical intervention for diagnosis/treatment of endometriosis in adolescents with dysmenorrhea and/or those who have difficulty participating in normal activities, are missing school, or avoiding extracurricular activities because of pelvic pain. (See <a class="local">'Trial of medical therapy for dysmenorrhea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the pain evaluation suggests a nonacute gynecologic source, we suggest medical treatment of dysmenorrhea/endometriosis rather than laparoscopy for diagnosis and therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'NSAIDs and hormonal therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest nonsteroidal anti-inflammatory agents and cyclic hormonal therapy for first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A three-month trial is a reasonable approach. (See <a class="local">'NSAIDs and hormonal therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of laparoscopy</strong> – Patients who do not respond to medical therapy within three months should undergo laparoscopy to make a definitive diagnosis and undergo ablation/resection of lesions and/or adhesions. Fifty to 70 percent of adolescents with chronic pelvic pain have endometriosis diagnosed at the time of laparoscopy. A gynecologist familiar with the appearance and treatment of endometriosis in adolescents should perform the surgical laparoscopic procedure. The laparoscopic appearance of endometriosis may be subtle, with red flame lesions and clear shiny peritoneal vesicles rather than powder burns. (See <a class="local">'Patients who fail therapy for dysmenorrhea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative medical treatment</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For medical management of confirmed endometriosis in adolescents ≤16 years of age, we suggest continuous hormonal therapy with either a combination estrogen-progestin or progestin therapy alone for first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Gonadotropin-releasing hormone (GnRH) agonists (with add-back therapy) are a second-line approach. (See <a class="local">'Postoperative medical treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adolescents &gt;16 years of age, we suggest either continuous combined hormonal contraception, progestin-only therapy, or GnRH agonists with add-back therapy as first-line therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See  <a class="medical medical_review" href="/z/d/html/7383.html" rel="external">"Endometriosis: Treatment of pelvic pain"</a> and <a class="local">'Postoperative medical treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Upon completion of GnRH agonist with add-back therapy for six to nine months, the patient begins a continuous combined hormonal contraceptive. If the patient is not able to tolerate continuous combination hormonal therapy, then we suggest long-term utilization of a GnRH agonist with add-back (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'GnRH agonists'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of recurrent pain</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prolonged GnRH agonist treatment</strong> – We have treated patients with surgically diagnosed disease refractory to other medications with prolonged GnRH agonist treatment plus add-back for over 14 years. (See <a class="local">'Management of recurrent pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitor bone mineral density</strong> – A baseline bone density evaluation should be obtained prior to starting retreatment with a GnRH agonist or if therapy is to be continued for over six months. If the patient remains on a GnRH agonist with add-back therapy, a bone density test should be obtained every two years. (See <a class="local">'Management of recurrent pain'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of repeat surgery</strong> – Pain that does not respond to aggressive medical therapy may be due to recurrent endometriosis, endometriomas, pelvic adhesions from endometriosis or prior surgery, or a new and different disease process. The majority of our patients have a single surgical procedure, but a repeat laparoscopic procedure can be considered for therapy in this clinical situation. (See <a class="local">'Management of recurrent pain'</a> above.)</p><p></p><p class="headingAnchor" id="H717785251"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Marc R Laufer, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Vercellini P, Fedele L, Arcaini L, et al. Laparoscopy in the diagnosis of chronic pelvic pain in adolescent women. J Reprod Med 1989; 34:827.</a></li><li><a class="nounderline abstract_t">Kontoravdis A, Hassan E, Hassiakos D, et al. Laparoscopic evaluation and management of chronic pelvic pain during adolescence. Clin Exp Obstet Gynecol 1999; 26:76.</a></li><li><a class="nounderline abstract_t">Goldstein DP, De Cholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care 1980; 1:37.</a></li><li><a class="nounderline abstract_t">Hirsch M, Dhillon-Smith R, Cutner AS, et al. The Prevalence of Endometriosis in Adolescents with Pelvic Pain: A Systematic Review. J Pediatr Adolesc Gynecol 2020; 33:623.</a></li><li class="breakAll">Laufer MR. Gynecologic Pain: Dysmenorrhea, Acute and Chronic Pelvic Pain, Endometriosis, and Premenstrual Syndrome. In: Pediatric &amp; Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Wolters Kluwer Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.238.</li><li><a class="nounderline abstract_t">Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 1996; 9:125.</a></li><li><a class="nounderline abstract_t">Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199.</a></li><li><a class="nounderline abstract_t">Ballweg ML. Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe. J Pediatr Adolesc Gynecol 2003; 16:S21.</a></li><li><a class="nounderline abstract_t">Laufer MR. Premenarcheal endometriosis without an associated obstructive anomaly: Presentation, diagnosis, and treatment. Fertil Steril 2000; 74:S15.</a></li><li><a class="nounderline abstract_t">Goldstein DP, deCholnoky C, Leventhal JM, Emans SJ. New insights into the old problem of chronic pelvic pain. J Pediatr Surg 1979; 14:675.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Mitsuhashi Y, Takaike T, et al. Tubal endometriosis diagnosed within one month after menarche: a case report. Tohoku J Exp Med 1997; 181:385.</a></li><li><a class="nounderline abstract_t">Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980; 137:327.</a></li><li><a class="nounderline abstract_t">Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 1927; 14:422.</a></li><li><a class="nounderline abstract_t">Schifrin BS, Erez S, Moore JG. Teen-age endometriosis. Am J Obstet Gynecol 1973; 116:973.</a></li><li><a class="nounderline abstract_t">Sanfilippo JS, Wakim NG, Schikler KN, Yussman MA. Endometriosis in association with uterine anomaly. Am J Obstet Gynecol 1986; 154:39.</a></li><li><a class="nounderline abstract_t">Halban, J. Hysteroadenosis metastica. Wien Klin Wochenschr 1924; 37:1205.</a></li><li><a class="nounderline abstract_t">Meyer, R. Uber entzundliche neterope epithelwucherungen im weiblichen Genetalg ebiet und uber eine bis in die Wurzel des Mesocolon ausgedehnte benigne Wucherung des Dar mepithel. Virch Arch Pathol Anat 1909; 195:487.</a></li><li><a class="nounderline abstract_t">Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol 1987; 70:115.</a></li><li><a class="nounderline abstract_t">Dmowski WP, Braun D, Gebel H. Endometriosis: genetic and immunologic aspects. Prog Clin Biol Res 1990; 323:99.</a></li><li><a class="nounderline abstract_t">Nothnick WB. Treating endometriosis as an autoimmune disease. Fertil Steril 2001; 76:223.</a></li><li><a class="nounderline abstract_t">Sasamoto N, Farland LV, Vitonis AF, et al. In utero and early life exposures in relation to endometriosis in adolescents and young adults. Eur J Obstet Gynecol Reprod Biol 2020; 252:393.</a></li><li><a class="nounderline abstract_t">Harris HR, Wieser F, Vitonis AF, et al. Early life abuse and risk of endometriosis. Hum Reprod 2018; 33:1657.</a></li><li><a class="nounderline abstract_t">Nodler JL, Harris HR, Chavarro JE, et al. Dairy consumption during adolescence and endometriosis risk. Am J Obstet Gynecol 2020; 222:257.e1.</a></li><li><a class="nounderline abstract_t">Doyle JO, Missmer SA, Laufer MR. The effect of combined surgical-medical intervention on the progression of endometriosis in an adolescent and young adult population. J Pediatr Adolesc Gynecol 2009; 22:257.</a></li><li><a class="nounderline abstract_t">Sasamoto N, Shafrir AL, Wallace BM, et al. Trends in pelvic pain symptoms over 2 years of follow-up among adolescents and young adults with and without endometriosis. Pain 2023; 164:613.</a></li><li><a class="nounderline abstract_t">DiVasta AD, Zimmerman LA, Vitonis AF, et al. Overlap Between Irritable Bowel Syndrome Diagnosis and Endometriosis in Adolescents. Clin Gastroenterol Hepatol 2021; 19:528.</a></li><li><a class="nounderline abstract_t">Walling MK, Reiter RC, O'Hara MW, et al. Abuse history and chronic pain in women: I. Prevalences of sexual abuse and physical abuse. Obstet Gynecol 1994; 84:193.</a></li><li><a class="nounderline abstract_t">Gagua T, Tkeshelashvili B, Gagua D, McHedlishvili N. Assessment of anxiety and depression in adolescents with primary dysmenorrhea: a case-control study. J Pediatr Adolesc Gynecol 2013; 26:350.</a></li><li><a class="nounderline abstract_t">Moen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand 1993; 72:560.</a></li><li><a class="nounderline abstract_t">Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod 2002; 17:2715.</a></li><li><a class="nounderline abstract_t">Kvaskoff M, Mu F, Terry KL, et al. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update 2015; 21:500.</a></li><li><a class="nounderline abstract_t">Nielsen NM, Jørgensen KT, Pedersen BV, et al. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome. Hum Reprod 2011; 26:1555.</a></li><li><a class="nounderline abstract_t">Harris HR, Costenbader KH, Mu F, et al. Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses' Health Study II. Ann Rheum Dis 2016; 75:1279.</a></li><li><a class="nounderline abstract_t">Miller JA, Missmer SA, Vitonis AF, et al. Prevalence of migraines in adolescents with endometriosis. Fertil Steril 2018; 109:685.</a></li><li><a class="nounderline abstract_t">Shafrir AL, Palmor MC, Fourquet J, et al. Co-occurrence of immune-mediated conditions and endometriosis among adolescents and adult women. Am J Reprod Immunol 2021; 86:e13404.</a></li><li><a class="nounderline abstract_t">Wright KN, Laufer MR. Endometriomas in adolescents. Fertil Steril 2010; 94:1529.e7.</a></li><li><a class="nounderline abstract_t">Pittaway DE, Fayez JA. The use of CA-125 in the diagnosis and management of endometriosis. Fertil Steril 1986; 46:790.</a></li><li><a class="nounderline abstract_t">Stratton P, Winkel C, Premkumar A, et al. Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis. Fertil Steril 2003; 79:1078.</a></li><li><a class="nounderline abstract_t">Tanaka YO, Itai Y, Anno I, et al. MR staging of pelvic endometriosis: role of fat-suppression T1-weighted images. Radiat Med 1996; 14:111.</a></li><li><a class="nounderline abstract_t">Ha HK, Lim YT, Kim HS, et al. Diagnosis of pelvic endometriosis: fat-suppressed T1-weighted vs conventional MR images. AJR Am J Roentgenol 1994; 163:127.</a></li><li><a class="nounderline abstract_t">Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.</a></li><li class="breakAll">Medical eligibility criteria for contraceptive use, Fifth edition. World Health Organization. 2015. www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/ (Accessed on January 22, 2019).</li><li><a class="nounderline abstract_t">ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent. Obstet Gynecol 2018; 132:e249. Reaffirmed 2022.</a></li><li><a class="nounderline abstract_t">Kistner RW. Treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones. Fertil Steril 1959; 10:539.</a></li><li><a class="nounderline abstract_t">Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80:560.</a></li><li><a class="nounderline abstract_t">Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98:771.</a></li><li><a class="nounderline abstract_t">Gambone JC, Mittman BS, Munro MG, et al. Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 2002; 78:961.</a></li><li><a class="nounderline abstract_t">Ling FW. Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. Obstet Gynecol 1999; 93:51.</a></li><li><a class="nounderline abstract_t">Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60:75.</a></li><li><a class="nounderline abstract_t">Propst AM, Laufer MR. Endometriosis in adolescents. Incidence, diagnosis and treatment. J Reprod Med 1999; 44:751.</a></li><li><a class="nounderline abstract_t">Matkovic V, Jelic T, Wardlaw GM, et al. Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model. J Clin Invest 1994; 93:799.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol 2019; 220:354.e1.</a></li><li class="breakAll">ESHRE Guideline Endometriosis. European Society of Human Reproduction and Embryology. February 2022. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline (Accessed on April 21, 2022).</li><li><a class="nounderline abstract_t">Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817.</a></li><li><a class="nounderline abstract_t">Davis GD, Thillet E, Lindemann J. Clinical characteristics of adolescent endometriosis. J Adolesc Health 1993; 14:362.</a></li><li><a class="nounderline abstract_t">Demco L. Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy. J Am Assoc Gynecol Laparosc 1998; 5:241.</a></li><li><a class="nounderline abstract_t">Laufer MR. Identification of clear vesicular lesions of atypical endometriosis: a new technique. Fertil Steril 1997; 68:739.</a></li><li><a class="nounderline abstract_t">Redwine DB, Yocom LB. A serial section study of visually normal pelvic peritoneum in patients with endometriosis. Fertil Steril 1990; 54:648.</a></li><li><a class="nounderline abstract_t">Nisolle M, Paindaveine B, Bourdon A, et al. Histologic study of peritoneal endometriosis in infertile women. Fertil Steril 1990; 53:984.</a></li><li><a class="nounderline abstract_t">Fedele L, Parazzini F, Bianchi S, et al. Stage and localization of pelvic endometriosis and pain. Fertil Steril 1990; 53:155.</a></li><li><a class="nounderline abstract_t">Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994; 62:696.</a></li><li><a class="nounderline abstract_t">Abbott J, Hawe J, Hunter D, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82:878.</a></li><li><a class="nounderline abstract_t">Song XC, Yu X, Luo M, et al. Clinical Characteristics and Postoperative Symptoms of 85 Adolescents with Endometriosis. J Pediatr Adolesc Gynecol 2020; 33:519.</a></li><li><a class="nounderline abstract_t">Cook AS, Rock JA. The role of laparoscopy in the treatment of endometriosis. Fertil Steril 1991; 55:663.</a></li><li><a class="nounderline abstract_t">Shim JY, Laufer MR. Adolescent Endometriosis: An Update. J Pediatr Adolesc Gynecol 2020; 33:112.</a></li><li><a class="nounderline abstract_t">Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril 1991; 56:628.</a></li><li><a class="nounderline abstract_t">Wright J, Lotfallah H, Jones K, Lovell D. A randomized trial of excision versus ablation for mild endometriosis. Fertil Steril 2005; 83:1830.</a></li><li><a class="nounderline abstract_t">Healey M, Ang WC, Cheng C. Surgical treatment of endometriosis: a prospective randomized double-blinded trial comparing excision and ablation. Fertil Steril 2010; 94:2536.</a></li><li><a class="nounderline abstract_t">Duffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev 2014; :CD011031.</a></li><li><a class="nounderline abstract_t">Healey M, Cheng C, Kaur H. To excise or ablate endometriosis? A prospective randomized double-blinded trial after 5-year follow-up. J Minim Invasive Gynecol 2014; 21:999.</a></li><li><a class="nounderline abstract_t">Pundir J, Omanwa K, Kovoor E, et al. Laparoscopic Excision Versus Ablation for Endometriosis-associated Pain: An Updated Systematic Review and Meta-analysis. J Minim Invasive Gynecol 2017; 24:747.</a></li><li><a class="nounderline abstract_t">Laufer MR, Einarsson JI. Surgical Management of Superficial Peritoneal Adolescent Endometriosis. J Pediatr Adolesc Gynecol 2019; 32:339.</a></li><li><a class="nounderline abstract_t">Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997; 68:1070.</a></li><li><a class="nounderline abstract_t">Unger CA, Laufer MR. Progression of endometriosis in non-medically managed adolescents: a case series. J Pediatr Adolesc Gynecol 2011; 24:e21.</a></li><li><a class="nounderline abstract_t">Yeung P Jr, Sinervo K, Winer W, Albee RB Jr. Complete laparoscopic excision of endometriosis in teenagers: is postoperative hormonal suppression necessary? Fertil Steril 2011; 95:1909.</a></li><li class="breakAll">Laufer MR, Einarsson JE. Surgical management of early stage adolescent endometriosis. Presented at the World Congress of Endometriosis, Canada, 2017.</li><li><a class="nounderline abstract_t">Sadler Gallagher J, Feldman HA, Stokes NA, et al. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial. J Pediatr Adolesc Gynecol 2017; 30:215.</a></li><li><a class="nounderline abstract_t">Lubianca JN, Gordon CM, Laufer MR. "Add-back" therapy for endometriosis in adolescents. J Reprod Med 1998; 43:164.</a></li><li><a class="nounderline abstract_t">Secura GM, Adams T, Buckel CM, et al. Change in sexual behavior with provision of no-cost contraception. Obstet Gynecol 2014; 123:771.</a></li><li><a class="nounderline abstract_t">Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab 2007; 92:2205.</a></li><li><a class="nounderline abstract_t">Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72:323.</a></li><li><a class="nounderline abstract_t">Moghissi KS, Boyce CR. Management of endometriosis with oral medroxyprogesterone acetate. Obstet Gynecol 1976; 47:265.</a></li><li><a class="nounderline abstract_t">Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175:396.</a></li><li><a class="nounderline abstract_t">Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997; 68:393.</a></li><li><a class="nounderline abstract_t">Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol 2012; 25:105.</a></li><li><a class="nounderline abstract_t">Brady PC, Missmer SA, Laufer MR. Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate. J Pediatr Adolesc Gynecol 2017; 30:422.</a></li><li><a class="nounderline abstract_t">Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study. Contraception 2009; 79:29.</a></li><li><a class="nounderline abstract_t">Ponpuckdee J, Taneepanichskul S. The effects of implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai 2005; 88 Suppl 2:S7.</a></li><li><a class="nounderline abstract_t">Al-Jefout M, Palmer J, Fraser IS. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. Aust N Z J Obstet Gynaecol 2007; 47:247.</a></li><li><a class="nounderline abstract_t">Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care 2005; 31:67.</a></li><li><a class="nounderline abstract_t">Yoost J, LaJoie AS, Hertweck P, Loveless M. Use of the levonorgestrel intrauterine system in adolescents with endometriosis. J Pediatr Adolesc Gynecol 2013; 26:120.</a></li><li class="breakAll">Barbieri RL. Treatment of endometriosis with the GnRH agonists. In: Gonadotropin Releasing Hormone Analogs: Applications in Gynecology, Barbieri RL, Friedman AJ (Eds), Elsevier Science, New York 1991. p.63.</li><li class="breakAll">Lupron depot - leuprolide acetate kit. US Food and Drug Administration (FDA) approved product information. Revised March 1, 2022. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on April 18, 2023).</li><li><a class="nounderline abstract_t">Hornstein MD, Surrey ES, Weisberg GW, Casino LA. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998; 91:16.</a></li><li><a class="nounderline abstract_t">Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166:740.</a></li><li><a class="nounderline abstract_t">Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99:709.</a></li><li><a class="nounderline abstract_t">Kiesel L, Schweppe KW, Sillem M, Siebzehnrübl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol 1996; 103 Suppl 14:15.</a></li><li><a class="nounderline abstract_t">DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial. Obstet Gynecol 2015; 126:617.</a></li><li><a class="nounderline abstract_t">Gallagher JS, Missmer SA, Hornstein MD, et al. Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis. J Pediatr Adolesc Gynecol 2018; 31:376.</a></li><li><a class="nounderline abstract_t">Divasta AD, Laufer MR, Gordon CM. Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis. J Pediatr Adolesc Gynecol 2007; 20:293.</a></li><li><a class="nounderline abstract_t">Kennedy SH, Williams IA, Brodribb J, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53:998.</a></li><li><a class="nounderline abstract_t">Wheeler JM, Knittle JD, Miller JD. Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. Am J Obstet Gynecol 1993; 169:26.</a></li><li><a class="nounderline abstract_t">Rock JA, Truglia JA, Caplan RJ. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. Obstet Gynecol 1993; 82:198.</a></li><li><a class="nounderline abstract_t">Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET). Fertil Steril 1992; 57:514.</a></li><li><a class="nounderline abstract_t">Crosignani PG, Gastaldi A, Lombardi PL, et al. Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial. Clin Ther 1992; 14 Suppl A:29.</a></li><li><a class="nounderline abstract_t">Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Fertil Steril 1992; 58:265.</a></li><li><a class="nounderline abstract_t">Shaw RW. Nafarelin in the treatment of pelvic pain caused by endometriosis. Am J Obstet Gynecol 1990; 162:574.</a></li><li><a class="nounderline abstract_t">Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982; 37:737.</a></li><li><a class="nounderline abstract_t">Buttram VC Jr, Reiter RC, Ward S. Treatment of endometriosis with danazol: report of a 6-year prospective study. Fertil Steril 1985; 43:353.</a></li><li><a class="nounderline abstract_t">Burry KA. Nafarelin in the management of endometriosis: quality of life assessment. Am J Obstet Gynecol 1992; 166:735.</a></li><li><a class="nounderline abstract_t">Shim JY, Laufer MR, Grimstad FW. Dysmenorrhea and Endometriosis in Transgender Adolescents. J Pediatr Adolesc Gynecol 2020; 33:524.</a></li><li><a class="nounderline abstract_t">Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005; 83:171.</a></li><li><a class="nounderline abstract_t">Ozawa Y, Murakami T, Tamura M, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertil Steril 2006; 86:1146.</a></li><li><a class="nounderline abstract_t">Olivares C, Bilotas M, Buquet R, et al. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod 2008; 23:2701.</a></li><li><a class="nounderline abstract_t">Laschke MW, Elitzsch A, Scheuer C, et al. Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertil Steril 2007; 87:163.</a></li><li><a class="nounderline abstract_t">Kyama CM, Mihalyi A, Simsa P, et al. Non-steroidal targets in the diagnosis and treatment of endometriosis. Curr Med Chem 2008; 15:1006.</a></li><li><a class="nounderline abstract_t">Smorgick N, Marsh CA, As-Sanie S, et al. Prevalence of pain syndromes, mood conditions, and asthma in adolescents and young women with endometriosis. J Pediatr Adolesc Gynecol 2013; 26:171.</a></li><li><a class="nounderline abstract_t">Wayne PM, Kerr CE, Schnyer RN, et al. Japanese-style acupuncture for endometriosis-related pelvic pain in adolescents and young women: results of a randomized sham-controlled trial. J Pediatr Adolesc Gynecol 2008; 21:247.</a></li><li><a class="nounderline abstract_t">Mansfield C, Lenobel D, McCracken K, et al. Impact of Pelvic Floor Physical Therapy on Function in Adolescents and Young Adults with Biopsy-Confirmed Endometriosis at a Tertiary Children's Hospital: A Case Series. J Pediatr Adolesc Gynecol 2022; 35:722.</a></li></ol></div><div id="topicVersionRevision">Topic 7415 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2529373" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Laparoscopy in the diagnosis of chronic pelvic pain in adolescent women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459441" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Laparoscopic evaluation and management of chronic pelvic pain during adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6458589" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Adolescent endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736134" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Prevalence of Endometriosis in Adolescents with Pelvic Pain: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32736134" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Prevalence of Endometriosis in Adolescents with Pelvic Pain: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8795787" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Endometriosis in an adolescent population: the Emory experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9391902" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12742183" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Premenarcheal endometriosis without an associated obstructive anomaly: Presentation, diagnosis, and treatment</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/162146" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New insights into the old problem of chronic pelvic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9163854" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tubal endometriosis diagnosed within one month after menarche: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7377252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Heritable aspects of endometriosis. I. Genetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4718224" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Teen-age endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3946502" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Endometriosis in association with uterine anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hysteroadenosis metastica</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Uber entzundliche neterope epithelwucherungen im weiblichen Genetalg ebiet und uber eine bis in die Wurzel des Mesocolon ausgedehnte benigne Wucherung des Dar mepithel</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110710" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Is endometriosis an autoimmune disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2406758" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endometriosis: genetic and immunologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11476764" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treating endometriosis as an autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32688135" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In utero and early life exposures in relation to endometriosis in adolescents and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30016439" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Early life abuse and risk of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31526789" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Dairy consumption during adolescence and endometriosis risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19646673" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The effect of combined surgical-medical intervention on the progression of endometriosis in an adolescent and young adult population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35947080" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Trends in pelvic pain symptoms over 2 years of follow-up among adolescents and young adults with and without endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184183" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Overlap Between Irritable Bowel Syndrome Diagnosis and Endometriosis in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041529" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Abuse history and chronic pain in women: I. Prevalences of sexual abuse and physical abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075089" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Assessment of anxiety and depression in adolescents with primary dysmenorrhea: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213105" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The familial risk of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12351553" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25765863" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endometriosis: a high-risk population for major chronic diseases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471158" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26238146" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses' Health Study II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605402" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prevalence of migraines in adolescents with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33583078" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Co-occurrence of immune-mediated conditions and endometriosis among adolescents and adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20334862" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endometriomas in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3465595" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The use of CA-125 in the diagnosis and management of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738499" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827803" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : MR staging of pelvic endometriosis: role of fat-suppression T1-weighted images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8010198" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diagnosis of pelvic endometriosis: fat-suppressed T1-weighted vs conventional MR images.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467196" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30461694" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : ACOG Committee Opinion No. 760: Dysmenorrhea and Endometriosis in the Adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969698" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704167" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413979" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9916956" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513962" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10509296" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Endometriosis in adolescents. Incidence, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8113412" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Timing of peak bone mass in Caucasian females and its implication for the prevention of osteoporosis. Inference from a cross-sectional model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30625295" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical diagnosis of endometriosis: a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30625295" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical diagnosis of endometriosis: a call to action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9130884" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Revised American Society for Reproductive Medicine classification of endometriosis: 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399247" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Clinical characteristics of adolescent endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9668144" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mapping the source and character of pain due to endometriosis by patient-assisted laparoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9341623" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Identification of clear vesicular lesions of atypical endometriosis: a new technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2209885" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A serial section study of visually normal pelvic peritoneum in patients with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2351237" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Histologic study of peritoneal endometriosis in infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2400415" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Stage and localization of pelvic endometriosis and pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926075" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482763" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32619717" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical Characteristics and Postoperative Symptoms of 85 Adolescents with Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1826275" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The role of laparoscopy in the treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31812704" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adolescent Endometriosis: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1833246" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15950657" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomized trial of excision versus ablation for mild endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20356588" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Surgical treatment of endometriosis: a prospective randomized double-blinded trial comparing excision and ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24696265" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Laparoscopic surgery for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768960" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : To excise or ablate endometriosis? A prospective randomized double-blinded trial after 5-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28456617" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Laparoscopic Excision Versus Ablation for Endometriosis-associated Pain: An Updated Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30708067" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Surgical Management of Superficial Peritoneal Adolescent Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9418699" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21126894" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Progression of endometriosis in non-medically managed adolescents: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420081" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Complete laparoscopic excision of endometriosis in teenagers: is postoperative hormonal suppression necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21420081" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Complete laparoscopic excision of endometriosis in teenagers: is postoperative hormonal suppression necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26927501" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9564639" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : "Add-back" therapy for endometriosis in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785603" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Change in sexual behavior with provision of no-cost contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17341557" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Formation of ethinyl estradiol in women during treatment with norethindrone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2970029" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1250555" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Management of endometriosis with oral medroxyprogesterone acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765259" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314903" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Progestins for symptomatic endometriosis: a critical analysis of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22154396" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28024920" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hepatic Adenomas in Adolescents and Young Women with Endometriosis Treated with Norethindrone Acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19041438" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis--a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722311" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The effects of implanon in the symptomatic treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17550495" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15720856" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518190" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Use of the levonorgestrel intrauterine system in adolescents with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518190" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Use of the levonorgestrel intrauterine system in adolescents with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518190" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Use of the levonorgestrel intrauterine system in adolescents with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9464714" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536260" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hormone treatment of endometriosis: the estrogen threshold hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978277" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916982" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Should add-back therapy for endometriosis be deferred for optimal results?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181088" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551430" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Long-Term Effects of Gonadotropin-Releasing Hormone Agonists and Add-Back in Adolescent Endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868896" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bone density in adolescents treated with a GnRH agonist and add-back therapy for endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140996" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A comparison of nafarelin acetate and danazol in the treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8333471" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336864" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531464" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. The Nafarelin European Endometriosis Trial Group (NEET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535020" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Leuprorelin acetate depot vs danazol in the treatment of endometriosis: results of an open multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386029" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137972" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nafarelin in the treatment of pelvic pain caused by endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7084496" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3979574" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Treatment of endometriosis with danazol: report of a 6-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1531576" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Nafarelin in the management of endometriosis: quality of life assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32535219" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Dysmenorrhea and Endometriosis in Transgender Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15652904" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16962108" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18716040" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17081538" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18393858" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Non-steroidal targets in the diagnosis and treatment of endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23507008" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prevalence of pain syndromes, mood conditions, and asthma in adolescents and young women with endometriosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794019" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Japanese-style acupuncture for endometriosis-related pelvic pain in adolescents and young women: results of a randomized sham-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35830927" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Impact of Pelvic Floor Physical Therapy on Function in Adolescents and Young Adults with Biopsy-Confirmed Endometriosis at a Tertiary Children's Hospital: A Case Series.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
